Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label randomized study of bitopertin in erythropoietic protoporphyria
2025-000481-28Phase 2
- Sponsor
- Disc Medicine
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bitopertin in erythropoietic protoporphyria (EPP) (2 arms), sponsored by Disc Medicine. Primary endpoint: Percent change from baseline in whole blood metal-free PPIX levels.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on 2025-000481-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000481-28.